Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EON: Etigilimab + Nivolumab in Platinum-resistant Ovarian Cancer
NCT05715216Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2021
- Primary completion
- Apr 2025
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of etigilimab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2021; status: active, not recruiting.
02
Drugs
etigilimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05715216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715216.